- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Off-label Can Be on Target
Las Vegas - Much of what is new in dermatologic therapy represents off-label use of marketed drugs, but clinicians should not let that fact necessarily deter them from prescribing what may be very safe and effective therapy, said Stephen Stone, M.D., at the Fall Clinical Dermatology Conference.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Optimizing Laser Therapy for Vascular Anomalies: Why Early Multidisciplinary Care Matters
Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD
The Future of Pediatric Care at MOPD
Updates on Treating Warts, Molluscum Contagiosum, and Other Pediatric Conditions
A Talk with Albert Yan, MD on Current Trends in Technology
An Analysis of Gender Differences in 4645 cases of Pediatric and Adolescent Melanoma
Sneak Peek at Best Sessions on Sunday at the Society for Pediatric Dermatology Meeting
Talking with Amy Paller, MD, about the Society for Pediatric Dermatology Meeting
Acne: Therapeutic Updates and Our Most Challenging Cases
Candrice Heath, MD, Discusses Her Presentation on Atopic Dermatitis in Skin of Color
Related Content
